The opportunity to redefine the treatment of major diseases is what drives everyone at Vertex. Our development portfolio represents the fruit of these efforts. Spend some time here and look around. Click on the pipeline chart to get information on our development programs and links to selected published articles. Go further and see how, just maybe, disease challenges may be overcome with innovation.

Lexiva
(HIV Infection)

Lexiva® (fosamprenavir calcium) is an HIV protease inhibitor developed by Vertex in collaboration with GlaxoSmithKline (GSK). Lexiva is dosed as two pills twice daily and as two pills once daily boosted by ritonavir and one pill twice daily boosted by ritonavir. Lexiva was approved in the U.S. in October 2003, and received approval in the E.U. under the trade name Telzir® in July 2004.

Click here for full prescribing information.